Private Equity-Backed Climatic Launches Inhalable Lung Health Device

Climatic emerged from stealth in April 2026 with a $10 million seed funding round, positioning itself at the intersection of preventative wellness and respiratory health innovation. The New York-based startup is developing L Max, a non-prescription daily inhalant supplement designed to support the lungs' natural ability to clear mucus, pollutants, and environmental particulate matter. The funding round was led by Lerer Hippeau, with participation from BBGV, Brand Foundry, Cade Ventures, Good Friends, and Space Station, reflecting strong venture backing for a category expansion play in consumer health.

L Max consists of five all-natural ingredients including sodium bicarbonate, citric acid, and the plant extract forskolin. According to in vivo studies conducted with Mount Sinai Medical Center of Florida, a single administration of the product improved mucus clearance by more than 50%, with measurable effects observed within minutes of use. The company has initiated a placebo-controlled, double-blind clinical study to further validate efficacy. In a five-week trial with endurance athletes, 98% of participants reported easier breathing during workouts, with an average 6% improvement in time trial performance, suggesting potential appeal to both general wellness consumers and performance-oriented athletes.

Co-founder and CEO Eric Kau brings substantial consumer brand-building experience, having spent over a decade developing consumer platforms at Chewy, Amazon, and Seed Health. Kau has articulated Climatic's market thesis: lung health remains almost entirely absent from daily wellness routines despite constant exposure to pollution, smoke, and allergens. The company is betting that entire industries built around sleep optimization, gut health, hydration, and exercise recovery demonstrate viable markets for preventative health categories, and that proactive lung care represents a similarly large opportunity.

The product is positioned as a daily ritual for health-conscious consumers already tracking metrics like heart rate variability and macronutrient intake but who have never applied the same intentionality to respiratory function. Early access began April 20, 2026, with a broader commercial launch scheduled for late spring 2026. The company views its addressable market as anyone who breathes, with particular emphasis on athletes and wellness-forward consumers seeking integrated health optimization.